Research graph
References from Arsenic-endemic regions correlate with elevated tumor mutational burden and genomic alterations in urothelial carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Bladder cancer survivorship.
10.1038/s41572-023-00468-9 · 2023 · External reference
Upper tract urothelial carcinoma (UTUC): prevalence, impact and management challenge.
10.2147/cmar.s445529 · 2024 · External reference
The impact of socioeconomic inequality on urological cancer: a nationwide population-based study in Taiwan.
10.4103/uros.uros_60_21 · 2022 · External reference
Prognostic significance of primary tumor location in upper tract urothelial carcinoma treated with nephroureterectomy: a retrospective, multi-center cohort study in Taiwan.
10.3390/jcm9123866 · 2020 · External reference
The cancer behavior and current treatment strategy for upper urinary tract cancer.
10.4103/uros.uros_58_22 · 2022 · External reference
A propensity score–matched analysis of the impact of carcinoma in situ on the clinical outcomes in patients with upper tract urothelial carcinomas—a nationwide multi-institutional cohort study.
10.1097/ju9.0000000000000098 · 2024 · External reference
Smoking history, smoking intensity, and type of cigarette as risk factors of bladder cancer: a literature review.
10.1097/mou.0000000000001242 · 2025 · External reference
Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area.
10.1186/s12885-021-07799-4 · 2021 · External reference
DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer.
10.1007/s00345-022-04100-5 · 2023 · External reference
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
10.3389/fimmu.2022.1097730 · 2022 · External reference
Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.
10.1001/jamaoncol.2022.1981 · 2022 · External reference
Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies.
10.3390/curroncol29030117 · 2022 · External reference
Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and RNA-based gene fusion analysis.
10.1093/oncolo/oyaf056 · 2025 · External reference
FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors.
10.1158/1078-0432.ccr-21-0327 · 2021 · External reference
COSMIC: the catalogue of somatic mutations in cancer.
10.1093/nar/gkad986 · 2024 · External reference
ClinVar: public archive of interpretations of clinically relevant variants.
10.1093/nar/gkad1044 · 2024 · External reference
Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium.
10.1158/1055-9965.epi-20-1090 · 2021 · External reference
High level of aristolochic acid detected with a unique genomic landscape predicts early UTUC onset after renal transplantation in Taiwan.
10.3389/fonc.2021.828314 · 2021 · External reference
Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression.
10.1016/bs.apha.2022.08.001 · 2023 · External reference
Molecular mechanisms of arsenic-induced disruption of DNA repair.
10.1007/s00018-023-04992-5 · 2023 · External reference
The role of H3K9me2-regulated base excision repair genes in the repair of DNA damage induced by arsenic in HaCaT cells and the effects of Ginkgo biloba extract intervention.
2023 · External reference
Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway.
10.1016/j.ygeno.2020.09.012 · 2020 · External reference
Genomic profiling of Chinese patients with urothelial carcinoma.
10.1186/s12885-021-07829-1 · 2021 · External reference
KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer.
10.1158/0008-5472.can-22-1444 · 2023 · External reference
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
10.1126/scitranslmed.aai8312 · 2017 · External reference
Dysregulation of the p300/CBP histone acetyltransferases in human cancer.
10.1080/17501911.2024.2447807 · 2025 · External reference
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
10.1016/j.gde.2024.102181 · 2024 · External reference
Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
10.1016/j.semcancer.2019.04.001 · 2019 · External reference
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
10.1016/j.pharmthera.2013.12.004 · 2014 · External reference
STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma.
10.1186/s12885-024-12130-y · 2024 · External reference
Loss of STK11 suppresses lipid metabolism and attenuates KRAS-induced immunogenicity in patients with non-small cell lung cancer.
10.1158/2767-9764.crc-24-0153 · 2024 · External reference
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma.
10.1200/po-25-00289 · 2025 · External reference
Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder.
10.1002/onco.13839 · 2021 · External reference
Comprehensive genomic characterization of upper tract urothelial carcinoma.
10.1016/j.eururo.2024.09.012 · 2025 · External reference
TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
10.1002/path.6266 · 2024 · External reference
HER2 and urothelial carcinoma: current understanding and future directions.
10.1038/s41585-025-01075-x · 2025 · External reference
Comparison between renal pelvic and ureteral tumors in muscle-invasive upper tract urothelial carcinoma.
10.1111/cas.15634 · 2023 · External reference
Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature.
10.1007/s11934-024-01245-1 · 2024 · External reference
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
10.37349/etat.2024.00240 · 2024 · External reference
Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels.
10.1001/jamaoncol.2022.1981 · ExternalCitation · doi-reference
Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder.
10.1002/onco.13839 · ExternalCitation · doi-reference
TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
10.1002/path.6266 · ExternalCitation · doi-reference
Molecular mechanisms of arsenic-induced disruption of DNA repair.
10.1007/s00018-023-04992-5 · ExternalCitation · doi-reference
DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer.
10.1007/s00345-022-04100-5 · ExternalCitation · doi-reference
Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature.
10.1007/s11934-024-01245-1 · ExternalCitation · doi-reference
Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression.
10.1016/bs.apha.2022.08.001 · ExternalCitation · doi-reference
Comprehensive genomic characterization of upper tract urothelial carcinoma.
10.1016/j.eururo.2024.09.012 · ExternalCitation · doi-reference
Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors.
10.1016/j.gde.2024.102181 · ExternalCitation · doi-reference
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
10.1016/j.pharmthera.2013.12.004 · ExternalCitation · doi-reference
Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
10.1016/j.semcancer.2019.04.001 · ExternalCitation · doi-reference
Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway.
10.1016/j.ygeno.2020.09.012 · ExternalCitation · doi-reference
Bladder cancer survivorship.
10.1038/s41572-023-00468-9 · ExternalCitation · doi-reference
HER2 and urothelial carcinoma: current understanding and future directions.
10.1038/s41585-025-01075-x · ExternalCitation · doi-reference
Dysregulation of the p300/CBP histone acetyltransferases in human cancer.
10.1080/17501911.2024.2447807 · ExternalCitation · doi-reference
ClinVar: public archive of interpretations of clinically relevant variants.
10.1093/nar/gkad1044 · ExternalCitation · doi-reference
COSMIC: the catalogue of somatic mutations in cancer.
10.1093/nar/gkad986 · ExternalCitation · doi-reference
Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and RNA-based gene fusion analysis.
10.1093/oncolo/oyaf056 · ExternalCitation · doi-reference
A propensity score–matched analysis of the impact of carcinoma in situ on the clinical outcomes in patients with upper tract urothelial carcinomas—a nationwide multi-institutional cohort study.
10.1097/ju9.0000000000000098 · ExternalCitation · doi-reference
Smoking history, smoking intensity, and type of cigarette as risk factors of bladder cancer: a literature review.
10.1097/mou.0000000000001242 · ExternalCitation · doi-reference
Comparison between renal pelvic and ureteral tumors in muscle-invasive upper tract urothelial carcinoma.
10.1111/cas.15634 · ExternalCitation · doi-reference
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
10.1126/scitranslmed.aai8312 · ExternalCitation · doi-reference
KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer.
10.1158/0008-5472.can-22-1444 · ExternalCitation · doi-reference
Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium.
10.1158/1055-9965.epi-20-1090 · ExternalCitation · doi-reference
FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors.
10.1158/1078-0432.ccr-21-0327 · ExternalCitation · doi-reference
Loss of STK11 suppresses lipid metabolism and attenuates KRAS-induced immunogenicity in patients with non-small cell lung cancer.
10.1158/2767-9764.crc-24-0153 · ExternalCitation · doi-reference
Comparative analysis of patients with upper urinary tract urothelial carcinoma in black-foot disease endemic and non-endemic area.
10.1186/s12885-021-07799-4 · ExternalCitation · doi-reference
Genomic profiling of Chinese patients with urothelial carcinoma.
10.1186/s12885-021-07829-1 · ExternalCitation · doi-reference
STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma.
10.1186/s12885-024-12130-y · ExternalCitation · doi-reference
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma.
10.1200/po-25-00289 · ExternalCitation · doi-reference
Upper tract urothelial carcinoma (UTUC): prevalence, impact and management challenge.
10.2147/cmar.s445529 · ExternalCitation · doi-reference
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
10.3389/fimmu.2022.1097730 · ExternalCitation · doi-reference
High level of aristolochic acid detected with a unique genomic landscape predicts early UTUC onset after renal transplantation in Taiwan.
10.3389/fonc.2021.828314 · ExternalCitation · doi-reference
Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies.
10.3390/curroncol29030117 · ExternalCitation · doi-reference
Prognostic significance of primary tumor location in upper tract urothelial carcinoma treated with nephroureterectomy: a retrospective, multi-center cohort study in Taiwan.
10.3390/jcm9123866 · ExternalCitation · doi-reference
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
10.37349/etat.2024.00240 · ExternalCitation · doi-reference
The cancer behavior and current treatment strategy for upper urinary tract cancer.
10.4103/uros.uros_58_22 · ExternalCitation · doi-reference
The impact of socioeconomic inequality on urological cancer: a nationwide population-based study in Taiwan.
10.4103/uros.uros_60_21 · ExternalCitation · doi-reference
